modafinil has been researched along with Amphetamine Abuse in 27 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we report the case of a patient with adult ADHD with co-morbid amphetamine abuse who was treated successfully with the non-stimulant alertness-promoting drug modafinil." | 7.75 | Modafinil treatment of amphetamine abuse in adult ADHD. ( Bitsios, P; Mann, N, 2009) |
| " In this study, we report the case of a patient with adult ADHD with co-morbid amphetamine abuse who was treated successfully with the non-stimulant alertness-promoting drug modafinil." | 3.75 | Modafinil treatment of amphetamine abuse in adult ADHD. ( Bitsios, P; Mann, N, 2009) |
| "Modafinil was found to be tolerable and well accepted by methamphetamine users and feasible for short-term inpatient withdrawal, but the sample was too small to detect treatment effects." | 2.78 | A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes. ( Ferris, J; Hester, R; Lee, N; McKetin, R; Nielsen, S; Pennay, A, 2013) |
| "Modafinil was tested for efficacy in decreasing use in methamphetamine-dependent participants, compared to placebo." | 2.77 | Modafinil for the treatment of methamphetamine dependence. ( Anderson, AL; Beresford, T; Biswas, K; Campbell, J; Chiang, N; Elkashef, AM; Haning, W; Holmes, T; Iturriaga, E; Kahn, R; Li, SH; Mawhinney, J; McCann, M; McSherry, F; Rawson, R; Stock, C; Weis, D; Yu, E, 2012) |
| "Modafinil has been shown to improve cognitive performance in neuropsychiatric patients and healthy volunteers." | 2.76 | Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. ( Ghahremani, DG; Hellemann, G; London, ED; Monterosso, J; Poldrack, RA; Tabibnia, G, 2011) |
| "Modafinil was safe and well tolerated and did not increase cigarette smoking." | 2.75 | Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. ( Cederblom, L; Heinzerling, KG; Kim, S; Ling, W; Moe, A; Shoptaw, S; Swanson, AN, 2010) |
| "Modafinil-treated participants had a milder withdrawal syndrome as measured by the Amphetamine Cessation Symptom Assessment and less sleep disturbance in comparison to mirtazapine." | 2.73 | Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. ( McGregor, C; Mitchell, A; Srisurapanont, M; White, JM; Wickes, W, 2008) |
| "Amphetamine dependence is a public health problem with medical, psychiatric, cognitive, legal and socioeconomic consequences." | 2.49 | Efficacy of psychostimulant drugs for amphetamine abuse or dependence. ( Capellà, D; Castells, X; Farre, M; Pérez-Mañá, C; Torrens, M, 2013) |
| "Pretreatment with modafinil (both 90 and 180 mg/kg) attenuated these effects but did not prevent METH induced decrease in locomotion." | 1.37 | Attenuated methamphetamine induced neurotoxicity by modafinil administration in mice. ( Bisagno, V; Giorgeri, S; Goitia, B; Peskin, V; Raineri, M; Taravini, IR; Urbano, FJ, 2011) |
| " By using the dosing time data collected, we determined that subjects who dosed at a consistent time daily were more likely to adhere to the prescribed regimen." | 1.37 | A simple, novel method for assessing medication adherence: capsule photographs taken with cellular telephones. ( Coyle, JR; Flower, K; Galloway, GP; Guillén, JE; Mendelson, JE, 2011) |
| "Modafinil (Provigil) is a wake-promoting drug characterized by cognitive enhancing abilities." | 1.36 | Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. ( Reichel, CM; See, RE, 2010) |
| "Modafinil was screened at various receptors and transporters using binding assays." | 1.35 | Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. ( Baumann, MH; Jain, R; Partilla, JS; Prisinzano, TE; Roth, BL; Rothman, RB; Setola, V; Zolkowska, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dias, VT | 2 |
| Vey, LT | 2 |
| Rosa, HZ | 2 |
| D'avila, LF | 2 |
| Barcelos, RCS | 2 |
| Burger, ME | 2 |
| Lee, NK | 1 |
| Jenner, L | 1 |
| Harney, A | 1 |
| Cameron, J | 1 |
| Pérez-Mañá, C | 1 |
| Castells, X | 1 |
| Torrens, M | 1 |
| Capellà, D | 1 |
| Farre, M | 1 |
| Dhillon, R | 1 |
| Wu, X | 1 |
| Bastiampillai, T | 1 |
| Tibrewal, P | 1 |
| Farah, MJ | 1 |
| Mann, N | 1 |
| Bitsios, P | 1 |
| Marsden, J | 1 |
| Shearer, J | 2 |
| Darke, S | 2 |
| Rodgers, C | 2 |
| Slade, T | 1 |
| van Beek, I | 2 |
| Lewis, J | 1 |
| Brady, D | 1 |
| McKetin, R | 3 |
| Mattick, RP | 2 |
| Wodak, A | 1 |
| Zolkowska, D | 1 |
| Jain, R | 1 |
| Rothman, RB | 1 |
| Partilla, JS | 1 |
| Roth, BL | 1 |
| Setola, V | 1 |
| Prisinzano, TE | 2 |
| Baumann, MH | 1 |
| McGaugh, J | 1 |
| Mancino, MJ | 1 |
| Feldman, Z | 1 |
| Chopra, MP | 1 |
| Gentry, WB | 1 |
| Cargile, C | 1 |
| Oliveto, A | 1 |
| De La Garza, R | 2 |
| Zorick, T | 1 |
| London, ED | 3 |
| Newton, TF | 2 |
| Heinzerling, KG | 1 |
| Swanson, AN | 1 |
| Kim, S | 1 |
| Cederblom, L | 1 |
| Moe, A | 1 |
| Ling, W | 1 |
| Shoptaw, S | 1 |
| Reichel, CM | 1 |
| See, RE | 1 |
| Shanahan, M | 1 |
| Hester, R | 2 |
| Lee, N | 2 |
| Pennay, A | 2 |
| Nielsen, S | 2 |
| Ferris, J | 2 |
| Ghahremani, DG | 1 |
| Tabibnia, G | 1 |
| Monterosso, J | 1 |
| Hellemann, G | 2 |
| Poldrack, RA | 1 |
| Raineri, M | 1 |
| Peskin, V | 1 |
| Goitia, B | 1 |
| Taravini, IR | 1 |
| Giorgeri, S | 1 |
| Urbano, FJ | 1 |
| Bisagno, V | 1 |
| Holtz, NA | 1 |
| Lozama, A | 1 |
| Carroll, ME | 1 |
| Anderson, AL | 1 |
| Li, SH | 1 |
| Biswas, K | 1 |
| McSherry, F | 1 |
| Holmes, T | 1 |
| Iturriaga, E | 1 |
| Kahn, R | 1 |
| Chiang, N | 1 |
| Beresford, T | 1 |
| Campbell, J | 1 |
| Haning, W | 1 |
| Mawhinney, J | 1 |
| McCann, M | 1 |
| Rawson, R | 1 |
| Stock, C | 1 |
| Weis, D | 1 |
| Yu, E | 1 |
| Elkashef, AM | 1 |
| Galloway, GP | 1 |
| Coyle, JR | 1 |
| Guillén, JE | 1 |
| Flower, K | 1 |
| Mendelson, JE | 1 |
| Dean, AC | 1 |
| Sevak, RJ | 1 |
| Monterosso, JR | 1 |
| Sugar, CA | 1 |
| Mahoney, JJ | 1 |
| Jackson, BJ | 1 |
| Kalechstein, AD | 1 |
| Chang, LC | 1 |
| Camacho, A | 1 |
| Stein, MB | 1 |
| McGregor, C | 1 |
| Srisurapanont, M | 1 |
| Mitchell, A | 1 |
| Wickes, W | 1 |
| White, JM | 1 |
| Kampman, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence[NCT00123370] | Phase 2 | 87 participants (Anticipated) | Interventional | 2006-07-31 | Active, not recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Evaluation of Modafinil vs Placebo for the Treatment of Methamphetamine Dependence[NCT00469508] | Phase 2 | 71 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence[NCT00123383] | Phase 2 | 10 participants (Anticipated) | Interventional | 2005-07-31 | Active, not recruiting | ||
| Phase2, Double-blind, Placebo-controlled Trial of Modafinil for the Treatment of Methamphetamine Dependence[NCT00520286] | Phase 2 | 210 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Behavioral Economics-Based Telehealth Intervention to Improve Post-MI Medication Adherence[NCT03022266] | 130 participants (Actual) | Interventional | 2017-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Self-reported depression: mean change on Beck Depression Index (BDI-II) assessed weekly during the 12 week medication phase. If the week12 measure was not available, the last observation was carried forward. 0 indicates no depression, 63 is the maximum indicating severe depression. (NCT00469508)
Timeframe: From baseline to end of treatment period (week 12).
| Intervention | units on a scale (Mean) |
|---|---|
| Modafinil | -11.8 |
| Placebo | -7 |
Urine samples, collected thrice weekly, were tested for metabolites of MA using radioimmunoassay. Each subject had a possible of 36 urine drug screens to provide during the 12 weeks of medication. An aggregate measure of urine drug screen results was calculated - the Treatment Effectiveness Score (TES) - which is the average of the sum of MA-free urine specimens provided during the treatment period by participants in each treatment condition. (NCT00469508)
Timeframe: From randomization to end of week 12
| Intervention | Clean urine drug screens (Mean) |
|---|---|
| Modafinil | 13.1 |
| Placebo | 12.7 |
The number of persons who completed the medication phase of the trial (12 weeks of medication). (NCT00469508)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Modafinil | 14 |
| Placebo | 13 |
To measure methamphetamine craving, mean change in craving based on visual analog scale (VAS) from 0 (not at all) to 100 (extremely) from baseline to the last week of observation during the 12 week treatment period. The last observation was carried forward if not available during week 12. (NCT00469508)
Timeframe: baseline and last observation during the 12 week treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Modafinil | -32.5 |
| Placebo | -47.3 |
Number of subjects with 21 or more consecutive days of abstinence (NCT00520286)
Timeframe: 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Modafinil | 32 |
| Placebo | 10 |
Number of participant who abstained from methamphetamine from weeks 1 through 12 (NCT00520286)
Timeframe: Weeks 1 - 12
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
| Modafinil | 27 | 38 | 39 | 46 | 41 | 39 | 34 | 40 | 35 | 34 | 37 | 34 |
| Placebo | 14 | 13 | 13 | 15 | 16 | 15 | 14 | 16 | 17 | 14 | 16 | 17 |
2 reviews available for modafinil and Amphetamine Abuse
| Article | Year |
|---|---|
Pharmacotherapy for amphetamine dependence: A systematic review.
Topics: Amphetamine; Amphetamine-Related Disorders; Dextroamphetamine; Humans; Medication Adherence; Methylp | 2018 |
Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; D | 2013 |
12 trials available for modafinil and Amphetamine Abuse
| Article | Year |
|---|---|
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
Topics: Adult; Amphetamine-Related Disorders; Australia; Benzhydryl Compounds; Central Nervous System Stimul | 2009 |
Open-label pilot study of modafinil for methamphetamine dependence.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Female; Humans; Male; Methamphetamine; M | 2009 |
Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Blood Pressure; Central Nervous System S | 2010 |
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimu | 2010 |
A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Cocai | 2010 |
A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Cocai | 2010 |
A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Cocai | 2010 |
A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Cocai | 2010 |
The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.
Topics: Adult; Amphetamine-Related Disorders; Attention; Benzhydryl Compounds; Central Nervous System Stimul | 2010 |
Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals.
Topics: Adult; Amphetamine-Related Disorders; Analysis of Variance; Association Learning; Benzhydryl Compoun | 2011 |
Modafinil for the treatment of methamphetamine dependence.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Combi | 2012 |
Acute modafinil effects on attention and inhibitory control in methamphetamine-dependent humans.
Topics: Adult; Amphetamine-Related Disorders; Attention; Benzhydryl Compounds; Case-Control Studies; Cogniti | 2011 |
Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Cogni | 2012 |
A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Doubl | 2013 |
Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.
Topics: Adult; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Centra | 2008 |
13 other studies available for modafinil and Amphetamine Abuse
| Article | Year |
|---|---|
Could Modafinil Prevent Psychostimulant Addiction? An Experimental Study in Rats.
Topics: Age Factors; Amphetamine; Amphetamine-Related Disorders; Animals; Antioxidants; Behavior, Animal; Be | 2017 |
Modafinil reduces amphetamine preference and prevents anxiety-like symptoms during drug withdrawal in young rats: Involvement of dopaminergic targets in VTA and striatum.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Anxiety; Central Nervous System Stimulants; Cor | 2019 |
Could modafinil be a drug of dependence?
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Disorders of Excessive Somnolence; Humans; Male | 2015 |
NEUROSCIENCE. The unknowns of cognitive enhancement.
Topics: Amphetamine-Related Disorders; Amphetamines; Benzhydryl Compounds; Biomedical Enhancement; Central N | 2015 |
Modafinil treatment of amphetamine abuse in adult ADHD.
Topics: Adult; Amphetamine-Related Disorders; Attention; Attention Deficit Disorder with Hyperactivity; Benz | 2009 |
The long road to pharmacotherapies for stimulant dependence.
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Moda | 2009 |
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Animal; Benzhydryl Compounds; Binding Sites; Centr | 2009 |
Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Addictive; Benzhydryl Compounds; Disease Models, A | 2010 |
Attenuated methamphetamine induced neurotoxicity by modafinil administration in mice.
Topics: Amphetamine-Related Disorders; Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Dru | 2011 |
Reinstatement of methamphetamine seeking in male and female rats treated with modafinil and allopregnanolone.
Topics: Amphetamine-Related Disorders; Animals; Benzhydryl Compounds; Central Nervous System Depressants; Ce | 2012 |
A simple, novel method for assessing medication adherence: capsule photographs taken with cellular telephones.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Cell Phone; Female; Humans; Male; Medica | 2011 |
Modafinil for social phobia and amphetamine dependence.
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbidity; | 2002 |
The search for medications to treat stimulant dependence.
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Brain; Bupropion; Cocaine; Cocaine-Related Diso | 2008 |